Join        Login             Stock Quote

Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders

Monday, February 11, 2013 4:17 PM

Branham Law, LLP announces that it is investigating AMAG Pharmaceuticals (NASDAQ: AMAG) and certain of its officers and directors for potential breaches of fiduciary duties in connection with AMAG’s apparent failure to disclose that users of the Company’s primary drug, Feraheme had suffered adverse reactions, including hospitalizations and one possible death.

Investors who purchased AMAG stock before January 1, 2010 and have held AMAG stock since, or anyone with information about this investigation should contact Branham Law, LLP at tbranham@branham-law.com or call (855) 722-5910.

On February 4, 2013, the United States First Circuit Court of Appeals reversed the district court’s dismissal of these claims and reinstated the action. After these failures to disclose were revealed, AMAG’s stock fell over $7.00 per share. Subsequent disclosures regarding the company’s rebate program resulted in a further drop of $4.02 per share.

Contact Trey Branham, Branham Law, LLP, 1-855-722-5910, 3900 Elm Street, Dallas, Texas 75226 for additional information.

(Source: Business Wire )
(Source: Quotemedia)


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.